Pfizer Canada Voluntarily Recalls One Lot of EpiPen® 0.3 mg and One Lot of EpiPen® Jr 0.15 mg (epinephrine) Auto-Injectors Click Here For More Details
Be Ready Healthcare Inc. is located in beautiful Sussex, New Brunswick Canada, a farming community centrally located an hour or less to the three major cities in New Brunswick, Saint John, Moncton and Fredericton. Our vision is to see publicly available epinephrine auto-injectors commonplace to treat all severe anaphylactic reactions and prevent any incidents from becoming fatal.
Major demographic, economic, geographic, social and cultural Factors
Demographic – Every person is susceptible. Many people have a known risk of anaphylaxis. They do not always carry or have immediate access to an epinephrine auto-injector. There are also cases of new allergies that were not previously known. As well, idiopathic (unknown causes) anaphylaxis is a real concern for many. Immediate access to epinephrine is essential to save lives. A pilot project in Sussex, N.B. was a classic case of this and saved a life only a few months after the initiation of publicly accessible epinephrine auto-injectors.
Economic – An epinephrine auto-injector (EAI) device is small, compact, easy to use, and secure. It can help an individual or others administer epinephrine, commonly referred to as EpiPen®. Two or more doses are often required depending on the severity of the allergy. In Canada, epinephrine auto-injectors are available behind the counter from a pharmacist.
Geographic - Seconds and minutes count with anaphylaxis. There are many rural settings and remote areas that have limited quick access to emergency services
Social – People are not prepared for several reasons: they do not know they are allergic to something and have a severe allergic reaction, they do not fill a prescription or purchase an EAI over the counter due to cost, they have an EAI however do not have it with them when they need it, they have severe allergic reactions with unknown causes (idiopathic). We have a focus on education to eliminate the fear of if, when and how to administer EAIs.
There is a lack of knowledge on how to administer the EAI. Most deaths are associated with no administration or a delayed administration of epinephrine. In particular teenagers do not want to be identified or be seen as having allergies. They do not carry it with them and do not want to be seen as “different”. Many children and/or teens are experiencing allergy bullying. Having highly visible unlocked cabinets, centrally located and alarmed will increase accessibility and awareness during the very stressful times of a severe anaphylactic reaction.